Screening and Prevention of Hereditary Gynecologic Cancers

Siobhan M. Kehoe, Noah D. Kauff

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Endometrial and ovarian cancer are the fourth and fifth most common malignancies in women, with approximately 40,000 new endometrial and 25,000 new ovarian cancers expected to be diagnosed in the Unites States this year. While the majority of these cancers will occur in the absence of a family history, approximately 5% of endometrial cancers and 10% of ovarian cancers will be the result of inherited defects in high-penetrance cancer susceptibility genes. With the identification and subsequent availability of clinical genetic testing for mutations in the genes associated with hereditary breast-ovarian cancer and the Lynch/hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, targeted risk-reduction using intensive screening, chemoprevention, and prophylactic surgery has become possible for women at inherited risk of gynecologic malignancies. We review the options for gynecologic cancer risk reduction in women with an inherited mutation in BRCA1, BRCA2, or one of the mismatch repair (MMR) genes associated with Lynch/HNPCC syndrome. Additionally, we outline ongoing questions and areas for future research.

Original languageEnglish (US)
Pages (from-to)406-410
Number of pages5
JournalSeminars in Oncology
Volume34
Issue number5
DOIs
StatePublished - Oct 2007

Fingerprint

Ovarian Neoplasms
Hereditary Nonpolyposis Colorectal Neoplasms
Risk Reduction Behavior
Endometrial Neoplasms
Neoplasms
Mutation
DNA Mismatch Repair
Penetrance
Neoplasm Genes
Chemoprevention
Genetic Testing
Genes
Breast Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Screening and Prevention of Hereditary Gynecologic Cancers. / Kehoe, Siobhan M.; Kauff, Noah D.

In: Seminars in Oncology, Vol. 34, No. 5, 10.2007, p. 406-410.

Research output: Contribution to journalArticle

@article{9190c2680f9f45c6a54e721cf15d72d5,
title = "Screening and Prevention of Hereditary Gynecologic Cancers",
abstract = "Endometrial and ovarian cancer are the fourth and fifth most common malignancies in women, with approximately 40,000 new endometrial and 25,000 new ovarian cancers expected to be diagnosed in the Unites States this year. While the majority of these cancers will occur in the absence of a family history, approximately 5{\%} of endometrial cancers and 10{\%} of ovarian cancers will be the result of inherited defects in high-penetrance cancer susceptibility genes. With the identification and subsequent availability of clinical genetic testing for mutations in the genes associated with hereditary breast-ovarian cancer and the Lynch/hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, targeted risk-reduction using intensive screening, chemoprevention, and prophylactic surgery has become possible for women at inherited risk of gynecologic malignancies. We review the options for gynecologic cancer risk reduction in women with an inherited mutation in BRCA1, BRCA2, or one of the mismatch repair (MMR) genes associated with Lynch/HNPCC syndrome. Additionally, we outline ongoing questions and areas for future research.",
author = "Kehoe, {Siobhan M.} and Kauff, {Noah D.}",
year = "2007",
month = "10",
doi = "10.1053/j.seminoncol.2007.07.004",
language = "English (US)",
volume = "34",
pages = "406--410",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Screening and Prevention of Hereditary Gynecologic Cancers

AU - Kehoe, Siobhan M.

AU - Kauff, Noah D.

PY - 2007/10

Y1 - 2007/10

N2 - Endometrial and ovarian cancer are the fourth and fifth most common malignancies in women, with approximately 40,000 new endometrial and 25,000 new ovarian cancers expected to be diagnosed in the Unites States this year. While the majority of these cancers will occur in the absence of a family history, approximately 5% of endometrial cancers and 10% of ovarian cancers will be the result of inherited defects in high-penetrance cancer susceptibility genes. With the identification and subsequent availability of clinical genetic testing for mutations in the genes associated with hereditary breast-ovarian cancer and the Lynch/hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, targeted risk-reduction using intensive screening, chemoprevention, and prophylactic surgery has become possible for women at inherited risk of gynecologic malignancies. We review the options for gynecologic cancer risk reduction in women with an inherited mutation in BRCA1, BRCA2, or one of the mismatch repair (MMR) genes associated with Lynch/HNPCC syndrome. Additionally, we outline ongoing questions and areas for future research.

AB - Endometrial and ovarian cancer are the fourth and fifth most common malignancies in women, with approximately 40,000 new endometrial and 25,000 new ovarian cancers expected to be diagnosed in the Unites States this year. While the majority of these cancers will occur in the absence of a family history, approximately 5% of endometrial cancers and 10% of ovarian cancers will be the result of inherited defects in high-penetrance cancer susceptibility genes. With the identification and subsequent availability of clinical genetic testing for mutations in the genes associated with hereditary breast-ovarian cancer and the Lynch/hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, targeted risk-reduction using intensive screening, chemoprevention, and prophylactic surgery has become possible for women at inherited risk of gynecologic malignancies. We review the options for gynecologic cancer risk reduction in women with an inherited mutation in BRCA1, BRCA2, or one of the mismatch repair (MMR) genes associated with Lynch/HNPCC syndrome. Additionally, we outline ongoing questions and areas for future research.

UR - http://www.scopus.com/inward/record.url?scp=34848847148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848847148&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2007.07.004

DO - 10.1053/j.seminoncol.2007.07.004

M3 - Article

C2 - 17920895

AN - SCOPUS:34848847148

VL - 34

SP - 406

EP - 410

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5

ER -